InnoCare Pharma 诺è¯å¥å(HKEX: 09969; SSE: 688428)
BioTech/Drugs - Beijing, Beijing, CN
InnoCare Pharma 诺è¯å¥å(HKEX: 09969; SSE: 688428) Employees
InnoCare Pharma 诺è¯å¥å(HKEX: 09969; SSE: 688428) Details
InnoCare Pharma is a commercial stage biopharmaceutical company dedicated to discovering, developing, and commercializing best-in-class and/or first-in-class drugs for the treatment of cancer and autoimmune diseases. InnoCare has strong in-house innovation capabilities, holding multiple foreign and domestic patents with a rich product pipeline target liquid tumors, solid tumors, and autoimmune diseases. Our team has discovered and developed a strong pipeline. InnoCare was co-founded by Professor Shi Yigong, a world-renowned structural biologist, and Dr. Cui Jisong, an outstanding leader in the biopharmaceutical industry. We have over 1000 employees. Our core R&D staff brings rich experience from the world's top pharmaceutical companies, such as Pfizer, GSK, Bristol-Myers Squibb, Merck, Johnson & Johnson, Bayer, etc. We are a truly global biopharmaceutical company with sites in Beijing, Nanjing, Shanghai, and Guangzhou, Hong Kong and Unites States. On March 23, 2020, InnoCare officially listed on the Hong Kong Stock Exchange (code: 9969). And on Sept. 21, 2023, InnoCare successfully got listed on STAR Board of Shanghai Stock Exchange (code: 688428). Our vision is to become a world-class biopharma leader to address the unmet medical needs globally.
InnoCare Pharma 诺è¯å¥å(HKEX: 09969; SSE: 688428) Technologies
Social Sharing
AddThis
Tag Management
Google Tag Manager
Other
Mobile Friendly
Hosting
Microsoft Azure Hosting
CSS and JavaScript Libraries
Bootstrap Framework